<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515448</url>
  </required_header>
  <id_info>
    <org_study_id>GENTAERO</org_study_id>
    <nct_id>NCT02515448</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia</brief_title>
  <acronym>GENTAERO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      Ventilator associated pneumonia (VAP) remains in the intensive care unit the infection
      associated with the highest morbidity and mortality.

      Respiratory infection with resistant organism are increasing in prevalence. Because of lack
      of alternatives, amino glycoside, old antibiotics family, can be used for several infection.

      Aerosolized Amikacin or Tobramycin are used in mechanically ventilated patients for
      respiratory infections. Gentamicin,which is effective against numerous multi drug resistant
      Gram-negative organism and Gram-positive like Staphylococcus aureus, could be a great option
      for nebulisation.

      The investigators assume that nebulisation of gentamicin allows to obtain a higher lung
      concentration while assuring a systematic toxicity much lesser than a parenteral
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Peak Plasma Concentration (Cmax)&quot;</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio deterioration above 20%.</measure>
    <time_frame>3 days</time_frame>
    <description>Bronchodilators used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Ventilator-associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Gentamicine injectable(day 1+2)and then gentamicine inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gentamicin</intervention_name>
    <arm_group_label>Gentamicine injectable(day 1+2)and then gentamicine inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  to be in critical care unit

          -  to be mechanically ventilated

          -  to have a ventilator-associated pneumonia requiring a treatment by gentamicin

          -  to be affiliated to a national insurance scheme

          -  to have given an informed consent (patient or close person)

        Exclusion Criteria:

          -  to be obese (BMI &gt; 40 kg/m²)

          -  to have been treated by gentamicin for 7 days

          -  to be allergic to aminoglycoside

          -  to have a severe respiratory failure (PaO2 / FiO2 &lt; 150)

          -  to have a renal failure (Cl creat &lt; 60 ml/min/1.73m²)

          -  to be under reinforced protection measure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BOISSON Matthieu</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dequin P-F</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VAP</keyword>
  <keyword>Critical care</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Gentamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

